Sept 18 (Reuters) - Immunomedics, Inc IMMU.O said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.
On Sunday, Gilead Sciences inc GILD.O said it would buy Immunomedics for $21 billion.
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.